The anti-cancer reactivity results are promising; two compounds (6a and 6d) were identified as most potent, safe, and as p53 activators in triple negative breast (MDA-MB 231) cancer cells to suppress expression, upregulating p21 expression by greater than three times and downregulating the expression of cyclin D and NF-kB. The gene discussed is NFKB1; the disease is cancer.